Hepatic Steatosis
Conditions
Brief summary
The goal of this clinical trial is to learn if Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease in adults. It will also learn about the safety of drug Longqi Jiangzhi decoction. Researchers will compare drug Longqi Jiangzhi decoction to a placebo (a look-alike substance that contains no drug) to see if drug Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease. Participants will: Take drug Longqi Jiangzhi decoction or a placebo every day for eight weeks Keep a record of their symptoms and the degree of hepatic steatosis before and after the treatment.
Interventions
DRUGLongqi Jiangzhi decoction
Below is the composition of Longqi Jiangzhi decoction: Gentiana Scabra 5g, Astragalus membranaceus 10g, Rhizoma Alismatis 10g, Crataegus pinnatifida 10g, Citri Reticulatae Pericarpium 5g.
DRUGControl placebo
The control placebo is a ten-fold dilution of the Longqi Jiangzhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug.
Sponsors
Shanghai Municipal Hospital of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The control placebo is a ten-fold dilution of the Longqi Jiangzhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug. An independent researcher (not involved in the trial operations or evaluations) is responsible for managing the randomization sequence and drug coding, and will distribute the appropriate drugs to participants at the right times. This ensures that the trial operators and evaluators are unaware of the treatment type; only the independent researcher has this knowledge. During the experiment, the assessment of treatment effects and the recording of adverse events are carried out by independent evaluators who are unaware of the treatment groups. Both the trial operators and the evaluators do not have access to the drug coding and randomization sequence.
Intervention model description
Participants are assigned to one of two groups in parallel for the duration of the study
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-50 years, both genders eligible; 2. Meets the diagnostic criteria for NAFLD; 3. Meets the diagnostic criteria for Traditional Chinese Medicine Spleen Deficiency and Damp-Heat Syndrome; 4. Has significant risk factors: CAP≥238dB/m, Body Mass Index (BMI) ≥23 kg/m²; 5. Has not received any anti-NAFLD medication treatment in the past month; 6. Normal major organ function, including heart, kidney, and liver functions, specifically: no significant abnormalities on electrocardiogram; normal serum creatinine and urea nitrogen; normal serum bilirubin and albumin levels; 7. Has sufficient cognitive and understanding abilities to comprehend the study content and its potential risks and benefits; 8. Voluntarily participates in the study and signs an informed consent form.
Exclusion criteria
1. Has liver steatosis due to other definitive causes, such as alcoholic liver disease, drug-induced liver injury, viral hepatitis infections (e.g., hepatitis B, hepatitis C, etc.); 2. Has other serious liver diseases, such as autoimmune liver diseases, primary biliary cholangitis, Wilson's disease, etc.; 3. Has severe dysfunction of major organs such as the heart, kidneys, lungs, etc., such as severe heart failure (NYHA functional classification III or above), renal failure (glomerular filtration rate eGFR \< 30 mL/min/1.73m²), acute exacerbation of chronic obstructive pulmonary disease, etc.; 4. Has other serious systemic diseases, such as malignant tumors, active systemic lupus erythematosus, etc.; 5. Known allergy or intolerance to any component of the study medication; 6. Has participated in another clinical trial within the last three months; 7. Pregnant women, lactating women, or women of childbearing age who refuse to use effective contraception during the trial; 8. Has severe mental illness or behavioral disorders that may affect adherence to the study protocol; 9. Other conditions that the researcher considers unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| controlled attenuation parameter | through study completion, an average of 8 weeks | A liver fiber diagnostic instrument (Fibro Touch) is used to perform instantaneous elastic hardness testing. The controlled attenuation parameter usually represents liver fat content, whereas higher scores mean a worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| body weight | through study completion, an average of 8 weeks | weighing on a scale |
| total cholesterol | through study completion, an average of 8 weeks | serum biochemistry |
| triglyceride | through study completion, an average of 8 weeks | serum biochemistry |
| alanine aminotransferase | through study completion, an average of 8 weeks | serum biochemistry |
| aspartate aminotransferase | through study completion, an average of 8 weeks | serum biochemistry |
| fasting plasma glucose | through study completion, an average of 8 weeks | serum biochemistry |
Other
| Measure | Time frame | Description |
|---|---|---|
| urea nitrogen | through study completion, an average of 8 weeks | serum biochemistry |
| creatinine | through study completion, an average of 8 weeks | serum biochemistry |
Outcome results
None listed